Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Chemoimmunotherapy With Toripalimab for Sinonasal Cancer

NCT06940180 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06940180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06940180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Chemoimmunotherapy With Toripalimab for Sinonasal Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2025
Completion date
February 1, 2029
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced head and neck cancer, paranasal sinus neoplasms, sinonasal cancer, sinonasal undifferentiated carcinoma, squamous cell carcinoma